Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects

References

• Del Paggio JC. Immunotherapy: cancer immunotherapy and the value of cure. Nat Rev Clin Oncol. 2018;15:268–270.
   PubMed Web of Science ®Google Scholar
• Liu M, Guo F. Recent updates on cancer immunotherapy. Precis Clin Med. 2018;1:65–74.
   PubMedGoogle Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
   PubMed Web of Science ®Google Scholar
• Lipowska-Bhalla G, Gilham DE, Hawkins RE, et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother. 2012;61:953–962.
   PubMed Web of Science ®Google Scholar
• Yang Y, Kohler ME, Chien CD, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017;9:eaag1209.
   PubMed Web of Science ®Google Scholar
• Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27:38–58.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood. 2012;119:2709–2720.
   PubMed Web of Science ®Google Scholar
• Vormittag P, Gunn R, Ghorashian S, et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164–181.
   PubMed Web of Science ®Google Scholar
• Younan PM, Peterson CW, Polacino P, et al. Lentivirus-mediated gene transfer in hematopoietic stem cells is impaired in SHIV-infected, ART-treated nonhuman primates. Mol Ther. 2015;23:943–951.
   PubMed Web of Science ®Google Scholar
• Piscopo NJ, Mueller KP, Das A, et al. Bioengineering solutions for manufacturing challenges in CAR T cells. Biotechnol J. 2018;13. DOI:10.1002/biot.201700095.
   PubMed Web of Science ®Google Scholar
• Vannucci L, Lai M, Chiuppesi F, et al. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol. 2013;36:1–22.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720–724.
   PubMed Web of Science ®Google Scholar
• Finney HM, Lawson AD, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161: 2791–2797.
   PubMed Web of Science ®Google Scholar
• Van Der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499–509.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 2009;106:3360–3365.
   PubMed Web of Science ®Google Scholar
• Zhong X-S, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell–mediated tumor eradication. Mol Ther. 2010;18:413–420.
   PubMed Web of Science ®Google Scholar
• Pulè MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933–941.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012;61:1269–1277.
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113–117.
   PubMed Web of Science ®Google Scholar
• Lohmueller JJ, Ham JD, Kvorjak M, et al. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2018;7:e1368604.
   Web of Science ®Google Scholar
• Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of t cell responses. Cell. 2018;173:1426–1438.
   PubMed Web of Science ®Google Scholar
• Graham C, Jozwik A, Pepper A, et al. Allogeneic CAR-T cells: more than ease of access? Cells 2018;7:155.
   PubMed Web of Science ®Google Scholar
• Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33:780–788.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113:6392–6402.
   PubMed Web of Science ®Google Scholar
• Jin C, Yu D, Essand M. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. Immunotherapy. 2016;8:1355–1361.
   PubMed Web of Science ®Google Scholar
• Hegde UP, Mukherji B. Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunol Immunother. 2017;66:1113–1121.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–856.
   PubMed Web of Science ®Google Scholar
• Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44:412–418.
   PubMed Web of Science ®Google Scholar
• Yeku OO, Purdon TJ, Koneru M, et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7:10541.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule–gated chimeric receptor. Science. 2015;350:aab4077.
   PubMed Web of Science ®Google Scholar
• Straathof KC, Pulè MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247–4254.
   PubMed Web of Science ®Google Scholar
• Wang X, Chang W-C, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255–1263.
   PubMed Web of Science ®Google Scholar
• Philip B, Kokalaki E, Mekkaoui L, et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood. 2014;124:1277–1287.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71–75.
   PubMed Web of Science ®Google Scholar
• Zah E, Lin MY, Silva-Benedict A, et al. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498–508.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105.
   PubMedGoogle Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.
   PubMed Web of Science ®Google Scholar
• Karlsson H, Svensson E, Gigg C, et al. Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS One. 2015;10:e0144787.
   PubMed Web of Science ®Google Scholar
• Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018;18:485–497.
   PubMed Web of Science ®Google Scholar
• Gauthier L, Corgnac S, Boutet M, et al. Paxillin binding to the cytoplasmic domain of CD103 promotes cell adhesion and effector functions for CD8+ resident memory T cells in tumors. Cancer Res. 2017;77:7072–7082.
   PubMed Web of Science ®Google Scholar
• Marelli-Berg FM, Clement M, Mauro C, et al. An immunologist's guide to CD31 function in T-cells. J Cell Sci. 2013;126:2343–2352.
   PubMed Web of Science ®Google Scholar
• Ferlito M, Irani K, Faraday N, et al. Nitric oxide inhibits exocytosis of cytolytic granules from lymphokine-activated killer cells. Proc Natl Acad Sci USA. 2006;103:11689–11694.
   PubMed Web of Science ®Google Scholar
• Zheng W, O'Hear CE, Alli R, et al. PPI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia. 2018;32:1157–1167.
   PubMed Web of Science ®Google Scholar
• Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol. 2013;4:20.
   PubMed Web of Science ®Google Scholar
• Kagoya Y, Nakatsugawa M, Yamashita Y, et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016;126:3479–3494.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904–917.
   PubMed Web of Science ®Google Scholar
• Almeida L, Lochner M, Berod L, et al. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28:514–524.
   PubMed Web of Science ®Google Scholar
• Dose M, Khan I, Guo Z, et al. c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood. 2006;108:2669–2677.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21:904–912.
   PubMed Web of Science ®Google Scholar
• Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med. 2018;24:705–706.
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–748.
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731–738.
   PubMed Web of Science ®Google Scholar
• Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz). 2010;58:107–119.
   PubMed Web of Science ®Google Scholar
• Hu WS, Hughes SH. HIV-1 reverse transcription. Cold Spring Harb Perspect Med. 2012;2:a006882.
   PubMed Web of Science ®Google Scholar
• Bukrinsky MI, Sharova N, Dempsey MP, et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA. 1992;89:6580–6584.
   PubMed Web of Science ®Google Scholar
• Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. Embo J. 1992;11:3053–3058.
   PubMed Web of Science ®Google Scholar
• Gallay P, Hope T, Chin D, et al. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci USA. 1997;94:9825–9830.
   PubMed Web of Science ®Google Scholar
• Meng B, Lever AM. Wrapping up the bad news: HIV assembly and release. Retrovirology. 2013;10:5.
   PubMed Web of Science ®Google Scholar
• Merten OW, Hebben M, Bovolenta C. Production of lentiviral vectors. Mol Ther Methods Clin Dev. 2016;3:16017.
   PubMed Web of Science ®Google Scholar
• Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 1993;90:8033–8037.
   PubMed Web of Science ®Google Scholar
• Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15:871–875.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu J, Zhong JF, et al. Engineering CAR-T cells. Biomark Res. 2017;5:22.
   PubMed Web of Science ®Google Scholar
• Bonini C, Brenner MK, Heslop HE, et al. Genetic modification of T cells. Biol Blood Marrow Transplant. 2011;17:S15–S20.
   PubMed Web of Science ®Google Scholar
• McGarrity GJ, Hoyah G, Winemiller A, et al. Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 2013;15:78–82.
   PubMed Web of Science ®Google Scholar
• Stripecke R, Kasahara N. Lentiviral and retroviral vector systems. In: Hunt KK, Vorburger SA, Swisher SG, editors. Gene Therapy for Cancer. Cancer Drug Discovery and Development. New York (USA): Humana Press Inc.; 2007. p. 39–71.
   Google Scholar
• El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release. 2004;94:1–14.
   PubMed Web of Science ®Google Scholar
• Pahle J, Walther W. Vectors and strategies for nonviral cancer gene therapy. Expert Opin Biol Ther. 2016;16:443–461.
   PubMed Web of Science ®Google Scholar
• Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501–510.
   PubMed Web of Science ®Google Scholar
• Ding S, Wu X, Li G, et al. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005;122:473–483.
   PubMed Web of Science ®Google Scholar
• Tipanee J, Chai YC, VandenDriessche T, et al. Preclinical and clinical advances in transposon-based gene therapy. Biosci Rep. 2017;37:BSR20160614.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112–120.
   PubMed Web of Science ®Google Scholar
• Ren J, Zhao Y. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell. 2017;8:634–643.
   PubMed Web of Science ®Google Scholar
• Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9:GE01–6.
   PubMed Web of Science ®Google Scholar
• Cribbs AP, Kennedy A, Gregory B, et al. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol. 2013;13:98.
   PubMed Web of Science ®Google Scholar
• Tang Y, Garson K, Li L, et al. Optimization of lentiviral vector production using polyethylenimine-mediated transfection. Oncol Lett. 2015;9:55–62.
   PubMed Web of Science ®Google Scholar
• Pham PL, Kamen A, Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol. 2006;34:225–237.
   PubMed Web of Science ®Google Scholar
• Sanber KS, Knight SB, Stephen SL, et al. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep. 2015;5:9021.
   PubMed Web of Science ®Google Scholar
• Broussau S, Jabbour N, Lachapelle G, et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther. 2008;16:500–507.
   PubMed Web of Science ®Google Scholar
• Sinn P, Sauter S, McCray P. Jr., Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors–design, biosafety, and production. Gene Ther. 2005;12:1089–1098.
   PubMed Web of Science ®Google Scholar
• Schweizer M, Merten O-W. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther. 2010;10:474–486.
   PubMed Web of Science ®Google Scholar
• Segura MM, Mangion M, Gaillet B, et al. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther. 2013;13:987–1011.
   PubMed Web of Science ®Google Scholar
• Merten O-W. Advances in cell culture: anchorage dependence. Philos Trans R Soc Lond B Biol Sci. 2014;370:20140040.
   Web of Science ®Google Scholar
• Kutner RH, Zhang X-Y, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc. 2009;4:495–505.
   PubMed Web of Science ®Google Scholar
• Ausubel LJ, Hall C, Sharma A, et al. Production of CGMP-grade lentiviral vectors. Bioprocess Int. 2012;10:32–43.
   PubMedGoogle Scholar
• Sheu J, Beltzer J, Fury B, et al. Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor. Mol Ther Methods Clin Dev. 2015;2:15020.
   PubMed Web of Science ®Google Scholar
• McCarron A, Donnelley M, McIntyre C, et al. Challenges of up-scaling lentivirus production and processing. J Biotechnol. 2016;240:23–30.
   PubMed Web of Science ®Google Scholar
• Ansorge S, Lanthier S, Transfiguracion J, et al. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures . J Gene Med. 2009;11:868–876.
   PubMed Web of Science ®Google Scholar
• Segura MM, Garnier A, Durocher Y, et al. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol Bioeng. 2007;98:789–799.
   PubMed Web of Science ®Google Scholar
• Marceau N, Gasmi M. Scalable lentiviral vector production system compatible with industrial pharmaceutical applications. International Publication Number WO2013076309A1. 2013. Available from https://patentimages.storage.googleapis.com/9b/e1/40/5fd1376c03af55/WO2013076309A1.pdf
   Google Scholar
• Valkama A, Leinonen H, Lipponen E, et al. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor. Gene Ther. 2018;25:39–46.
   PubMed Web of Science ®Google Scholar
• Yang S, Karne NK, Goff SL, et al. A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Hum Gene Ther Methods. 2012;23:73–83.
   PubMed Web of Science ®Google Scholar
• Kramberger P, Urbas L, Štrancar A. Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages. Hum Vaccin Immunother. 2015;11:1010–1021.
   PubMed Web of Science ®Google Scholar
• Reeves L, Cornetta K. Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther. 2000;7:1993–1998.
   PubMed Web of Science ®Google Scholar
• Bandeira V, Peixoto C, Rodrigues AF, et al. Downstream processing of lentiviral vectors: releasing bottlenecks. Hum Gene Ther Methods. 2012;23:255–263.
   PubMed Web of Science ®Google Scholar
• Vellinga J, Smith JP, Lipiec A, et al. Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther. 2014;25:318–327.
   PubMed Web of Science ®Google Scholar
• Prashad M, Tarrach K. Depth filtration: cell clarification of bioreactor offloads. Filtr Separat. 2006;43:28–30.
   Web of Science ®Google Scholar
• Negrete A, Pai A, Shiloach J. Use of hollow fiber tangential flow filtration for the recovery and concentration of HIV virus-like particles produced in insect cells. J Virol Methods. 2014;195:240–246.
   PubMed Web of Science ®Google Scholar
• Merten O-W, Schweizer M, Chahal P, et al. Manufacturing of viral vectors: part II. Downstream processing and safety aspects. Pharm Bioprocess. 2014;2:237–251.
   Google Scholar
• Papanikolaou E, Kontostathi G, Drakopoulou E, et al. Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation. Virus Res. 2013;175:1–11.
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Scheibe O, Kocourek A, et al. Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration. BMC Biotechnol. 2011;11:55.
   PubMed Web of Science ®Google Scholar
• Jiang W, Hua R, Wei M, et al. An optimized method for high-titer lentivirus preparations without ultracentrifugation. Sci Rep. 2015;5:13875.
   PubMed Web of Science ®Google Scholar
• Cooper AR, Patel S, Senadheera S, et al. Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J Virol Methods. 2011;177:1–9.
   PubMed Web of Science ®Google Scholar
• Merten OW, Charrier S, Laroudie N, et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther. 2011;22:343–356.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341:1233151.
   PubMed Web of Science ®Google Scholar
• Segura MM, Kamen A, Garnier A. Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv. 2006;24:321–337.
   PubMed Web of Science ®Google Scholar
• Rajamanickam V, Herwig C, Spadiut O. Monoliths in bioprocess technology. Chromatography. 2015;2:195–212.
   Google Scholar
• Marino MP, Panigaj M, Ou W, et al. A scalable method to concentrate lentiviral vectors pseudotyped with measles virus glycoproteins. Gene Ther. 2015;22:280–285.
   PubMed Web of Science ®Google Scholar
• Teepakorn C, Fiaty K, Charcosset C. Comparison of membrane chromatography and monolith chromatography for lactoferrin and bovine serum albumin separation. Processes. 2016;4:31.
   Web of Science ®Google Scholar
• Hormann K, Müllner T, Bruns S, et al. Morphology and separation efficiency of a new generation of analytical silica monoliths. J Chromatogr A. 2012;1222:46–58.
   PubMed Web of Science ®Google Scholar
• Lesch H, Laitinen A, Peixoto C, et al. Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. Gene Ther. 2011;18:531–538.
   PubMed Web of Science ®Google Scholar
• Bellintani F, Piacenza L, Birolo RS, et al. Large scale process for the production and purification of lentiviral vectors for clinical applications. Hum Gene Ther. 2008;19:1089. ESGCT 2008 Oral presentation 35.
   Web of Science ®Google Scholar
• de las Mercedes Segura M, Garnier A, Kamen A. Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. J Virol Methods. 2006;133:82–91.
   PubMed Web of Science ®Google Scholar
• Heider S, Muzard J, Zaruba M, et al. Integrated method for purification and single-particle characterization of lentiviral vector systems by size exclusion chromatography and tunable resistive pulse sensing. Mol Biotechnol. 2017;59:251–259.
   PubMed Web of Science ®Google Scholar
• Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.
   PubMed Web of Science ®Google Scholar
• Amitabha D, Nebelitsky E, Slepushkin V. Buffers for stabilization of lentiviral preparations. 2016. Available from https://patentimages.storage.googleapis.com/bb/e7/3b/94d2f4beb0bbc4/WO2017087861A1.pdf
   Google Scholar
• Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Hum Genet. 2007;Chapter 12:Unit 12.10.
   PubMedGoogle Scholar
• Barde I, Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Neurosci. 2010;Chapter 4:Unit 4.21.
   PubMedGoogle Scholar
• Geraerts M, Willems S, Baekelandt V, et al. Comparison of lentiviral vector titration methods. BMC Biotechnol. 2006;6:34.
   PubMed Web of Science ®Google Scholar
• Ding B, Kilpatrick DL. Lentiviral vector production, titration, and transduction of primary neurons. Methods Mol Biol. 2013;1018:119–131.
   PubMedGoogle Scholar
• Sena-Esteves M, Gao G. Titration of lentivirus vectors. Cold Spring Harb Protoc. 2018;2018:pdb.prot095695.
   Google Scholar
• Radcliffe PA, Sion CJ, Wilkes FJ, et al. Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Ther. 2008;15:289–297.
   PubMed Web of Science ®Google Scholar
• Shen CJ, Yang YX, Han EQ, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol. 2013;6:33.
   PubMed Web of Science ®Google Scholar
• Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J. 2012;443:603–618.
   PubMed Web of Science ®Google Scholar
• Sastry L, Johnson T, Hobson MJ, et al. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 2002;9:1155–1162.
   PubMed Web of Science ®Google Scholar
• Murphy ME, Vin CD, Slough MM, et al. Design of a titering assay for lentiviral vectors utilizing direct extraction of DNA from transduced cells in microtiter plates. Mol Ther Methods Clin Dev. 2016;3:16005.
   PubMed Web of Science ®Google Scholar
• Unger C, Skottman H, Blomberg P, et al. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Gen. 2008;17:R48–R53.
   PubMed Web of Science ®Google Scholar
• van der Loo JC, Wright JF. Progress and challenges in viral vector manufacturing. Hum Mol Genet. 2016;25:R42–R52.
   PubMed Web of Science ®Google Scholar
• Dropulic B, Schonely K, Slepushkin V, et al. QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioprocess J. 2003;2:39–47.
   Google Scholar
• Cesana D, Volpin M, Secanechia YNS, et al. Safety and efficacy of retroviral and lentiviral vectors for gene therapy. In Brunetti-Pierri N, editor. Safety and efficacy of gene-based therapeutics for inherited disorders. Basingstoke (UK): Springer, 2017. p. 9–35.
   Google Scholar
• von Kalle C, Deichmann A, Schmidt M. Vector integration and tumorigenesis. Hum Gene Ther. 2014;25:475–481.
   PubMed Web of Science ®Google Scholar
• Uhlig KM, Schülke S, Scheuplein VA, et al. Lentiviral protein transfer vectors are an efficient vaccine-platform inducing strong antigen-specific cytotoxic T cell response. J Virol. 2015;89:9044–9060.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Development and manufacture of lentiviral vectors. 2005. Reference number CPMP/BWP/2458/03. Available from https://www.ema.europa.eu/en/development-manufacture-lentiviral-vectors
   Google Scholar
• Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther. 2008;15:840–848.
   PubMed Web of Science ®Google Scholar
• Stacey GN, Merten OW. Host cells and cell banking. Methods Mol Biol. 2011;737:45–88.
   PubMedGoogle Scholar
• Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother. 2016;2:28–35.
   Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–1700.
   PubMed Web of Science ®Google Scholar
• Levine B. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22:79–84.
   PubMed Web of Science ®Google Scholar
• Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32:169–180.
   PubMed Web of Science ®Google Scholar
• Singh H, Moyes J, Huls M, et al. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther. 2015;22:95–100.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73–95ra73.
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PloS One. 2013;8:e64138.
   PubMed Web of Science ®Google Scholar
• Ghassemi S, Bedoya F, Nunez-Cruz S, et al. Shortened T cell culture with IL-7 and IL-15 provides the most potent chimeric antigen receptor (CAR)-modified T cells for adoptive immunotherapy. J Immunol. 2016;196:214.
   Google Scholar
• Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15:981–988.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Ciurea SO, Huls MH, et al. Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. Am Soc Hematol. 2015;126:862.
   Google Scholar
• Ghassemi S, Nunez-Cruz S, O'Connor RS, et al. Reducing ex vivo culture improves the anti-leukemic activity of Chimeric Antigen Receptor (CAR)-T cells. Cancer Immunol Res. 2018;6:1100–1109.
   PubMed Web of Science ®Google Scholar
• Gogol-Doring A, Ammar I, Gupta S, et al. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T Cells. Mol Ther. 2016;24:592–606.
   PubMed Web of Science ®Google Scholar
• Li R, Zhuang Y, Han M, et al. piggyBac as a high-capacity transgenesis and gene-therapy vector in human cells and mice. Dis Model Mech. 2013;6:828–833.
   PubMed Web of Science ®Google Scholar
• Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol. 2016;3:16015.
   PubMed Web of Science ®Google Scholar
• Wang X, Riviere I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015;22:85–94.
   PubMed Web of Science ®Google Scholar
• Singh H, Huls H, Kebriaei P, et al. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD 19. Immunol Rev. 2014;257:181–190.
   PubMed Web of Science ®Google Scholar
• Galeano Nino JL, Kwan RY, Weninger W, et al. Antigen-specific T cells fully conserve antitumour function following cryopreservation. Immunol Cell Biol. 2016;94:411–418.
   PubMed Web of Science ®Google Scholar
• Witts R, Tennant M, Chrobak K, et al. Determination of an optimal formulation for CAR-T Cells: cryopreservation studies using model T-cells. Poster 2017. Available from: https://www.biolifesolutions.com/wp-content/uploads/2017/03/WittsR_Pfizer-ECI2017_Jan2017_Poster.pdf
   Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024–10028.
   PubMed Web of Science ®Google Scholar
• Townsend MH, Shrestha G, Robison RA, et al. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res. 2018;37:163.
   PubMed Web of Science ®Google Scholar
• Elahi R, Khosh E, Tahmasebi S, et al. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol 2018;9:1717.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee D-Y. Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus. Ann Pediatr Endocrinol Metab. 2015;20:69–73.
   PubMedGoogle Scholar
• Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119–122.
   PubMed Web of Science ®Google Scholar
• Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:35.
   PubMed Web of Science ®Google Scholar
• Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4.
   PubMed Web of Science ®Google Scholar
• Titov A, Petukhov A, Staliarova A, et al. The biological basis and clinical symptoms of CAR-T therapy-associated toxicities. Cell Death Dis. 2018;9:897.
   PubMed Web of Science ®Google Scholar
• Sun S, Hao H, Yang G, et al. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:1.
   Google Scholar
• Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–1854.
   PubMed Web of Science ®Google Scholar
• Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012;14:405–415.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–2554.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–851.
   PubMed Web of Science ®Google Scholar
• Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30:123–129.
   PubMed Web of Science ®Google Scholar
• Rubtsova MP, Vasilkova DP, Malyavko AN, et al. Telomere lengthening and other functions of telomerase. Acta Naturae. 2012;4:44–61.
   PubMed Web of Science ®Google Scholar
• Bai Y, Kan S, Zhou S, et al. Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. Cell Discov. 2015;1:15040.
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453–1464.
   PubMed Web of Science ®Google Scholar
• Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007;179:4910–4918.
   PubMed Web of Science ®Google Scholar
• Dai H, Zhang W, Li X, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 2015;4:e1027469.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. Am Soc Clin Invest. 2016;126:2123–2138.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang M, Ramos C, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Am Soc Hematol. 2014;123:3750–3759.
   Google Scholar
• Finney HM, Akbar AN, Lawson A. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol. 2004;172:104–113.
   PubMed Web of Science ®Google Scholar
• D'Aloia MM, Zizzari IG, Sacchetti B, et al. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9:282.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Rössig C, Calonge MJ, et al. Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity. Am Soc Hematol. 2002;99:3179–3187.
   Google Scholar
• Kono K, Ressing ME, Brandt RM, et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res. 1996;2:1825–1828.
   PubMed Web of Science ®Google Scholar
• Kono K, Salazar Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26:1308–1313.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Jackson HJ, Yeku O, et al. Enhancing CAR T cell anti-tumor efficacy through secreted single chain variable fragment (scFv) immune checkpoint blockade. Blood. 2017;130:842.
   PubMed Web of Science ®Google Scholar
• Cadilha B, Dorman K, Rataj F, et al. Enabling T Cell recruitment to tumours as a strategy for improving adoptive t cell therapy. Eur Oncol Haematol. 2017;13:66–73.
   Google Scholar
• Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers. 2017;9:pii:E92.
   PubMed Web of Science ®Google Scholar
• Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016;3:16006.
   PubMed Web of Science ®Google Scholar